Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

(2008) O. Gluz et al.   ANNALS OF ONCOLOGY

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

(2008) Jiyoung Rhee et al.   BMC CANCER

Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers

(2008) Marta Guix et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Nestin is expressed in basal-like and triple negative breast cancers

(2008) S Parry et al.   JOURNAL OF CLINICAL PATHOLOGY

Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype

(2007) B Mahler-Araujo et al.   JOURNAL OF CLINICAL PATHOLOGY